NEW YORK (GenomeWeb News) – Genetic Technologies said on Thursday that receipts from customers for its first quarter of Fiscal Year 2014 dropped 17 percent.

For the three months ended Sept. 30, receipts totaled A$1.0 million (US$945,000) down from $A1.2 million, a year ago. The downtick occurred despite a record number of test samples for its flagship non-familial breast cancer risk assessment test called BrevaGen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.